A New Technique for Zero Fluoroscopy Atrial Fibrillation Ablation Without the Use of Intracardiac Echocardiography

INTRODUCTION

- Efforts to reduce radiation exposure during invasive procedures include a novel three-dimensional (3D) electroanatomic mapping-based technique developed by Guarguagli et al. for zero-fluoroscopy radiofrequency (RF) catheter ablation for atrial fibrillation.
- This case report describes the use of the NRG™ Transseptal Needle (Baylis Medical®) to facilitate fluoroless left atrial access in a patient with cardiac anatomy complicated by persistent left superior caval vein (LSCV), as well as two prior right atrial flutter ablations.

METHODS

Imaging setup

- A 3D map of the right atrium and coronary sinus (CS) was created using a bidirectional CARTO® Catheter (Biosense Webster), and combined with a pre-procedural cardiac magnetic resonance scan.
- The resulting map allowed visualization and localization of two decapolar reference catheters that were placed at the CS and the bundle of His.

Transseptal puncture

- The mapping catheter was used to introduce a long sheath into the superior vena cava.
- The NRG™ Transseptal Needle, when exposed outside the sheath, was visualized as a bipolar catheter on the CARTO® Map as it was advanced towards the superior caval vein and dropped down onto the interatrial septum.
- Right and left anterior oblique projections of the map were used to confirm needle tip position on the fossa ovalis prior to applying RF energy for transseptal puncture (pulsed mode, monopolar power for 600 ms).
- Intracardiac pressure was monitored from the side holes at the tip of the RF needle to confirm left atrial access.
- This procedure was performed twice for double transseptal puncture.

RF ablation

- Mapping of the left atrium and pulmonary veins (PVs) was carried out after obtaining left atrial access.
- Ipsilateral PV isolation and complex fractionated atrial electrograms ablation in both atria, as well as LCSV, were performed.

DISCUSSION AND CONCLUSIONS

- The catheter ablation procedure was completed in 146 min with no use of fluoroscopy.
- Achieving transseptal puncture by visualization of the NRG™ Transseptal Needle using CARTO® Electroanatomic Mapping and pre-procedural cardiac magnetic resonance scans completely eliminated radiation exposure, despite the complex cardiac anatomy described in this case.
Brief Summary | NRG™ Transseptal Needle

**CAUTION:** Federal law (USA) restricts this device to sale by or on the order of a physician. Rx only. Prior to use, please see the complete "Instructions for Use" for more information on Indications, Contraindications, Warnings, Precautions, Adverse Events, and Operator’s Instructions.

**INDICATIONS FOR USE:** The NRG™ Transseptal Needle is used to create an atrial septal defect in the heart. Secondary indications include monitoring intracardiac pressures, sampling blood, and infusing solutions.

**CONTRAINDICATIONS:** The NRG™ Transseptal Needle is not recommended for use with any conditions that do not require cutting or coagulation of soft tissue.

**WARNINGS:** Laboratory staff and patients can undergo significant x-ray exposure during radiofrequency puncture procedures due to the continuous usage of fluoroscopic imaging. This exposure can result in acute radiation injury as well as increased risk for somatic and genetic effects. Therefore, adequate measures must be taken to minimize this exposure. The NRG™ Transseptal Needle is intended for single patient use only. Do not attempt to sterilize and reuse the needle. Reuse can cause the patient injury and/or the communication of infectious disease(s) from one patient to another. Failure to do so may result in patient complications. The NRG™ Transseptal Needle must be used with the BMC Connector Cable. Attempts to use it with other connector cables can result in electrocution of the patient and/or operator.

**PRECAUTIONS:** Placement of the dispersive electrode on the thigh or hip could be associated with higher impedance. In order to prevent the risk of ignition make sure that flammable material is not present in the room during RF power application. Careful needle manipulation must be performed to avoid cardiac damage, or tamponade. Needle advancement should be done under image guidance. If resistance is encountered, DO NOT use excessive force to advance or withdraw the needle. During power delivery, the patient should not be allowed to come in contact with ground metal surfaces. Thoroughly flush the NRG™ Transseptal Needle with heparinized saline solution prior to use. If using electroanatomical mapping guidance it is recommended to confirm tip placement on the fossa ovalis and septal tenting before RF puncture with graphic imaging or another imaging modality.

**ADVERSE EVENTS:** Adverse events that may occur while using the Baylis Medical Radiofrequency Puncture System include: Tamponade • Sepsis/Infection • Thromboembolic episodes • Vessel perforation • Atrial Fibrillation • Myocardial Infarction • Vessel spasm • Sustained arrhythmias • Atrial Flutter • Hemorrhage • Vascular thrombosis • Perforation of the myocardium • Hematoma • Allergic reaction to contrast medium • Ventricular Tachycardia • Pain and Tenderness • Thermal damage to tissue • Arteriovenous fistula • Pericardial Effusion

All trademarks are property of their respective owners. Patents Pending and/or issued. CAUTION: The law restricts these devices to sale by or on the order of a physician. Rx only. Indications, Contraindications, Warnings, and Instructions For Use can be found in the product labelling supplied with each device or at www.baylismedical.com.

This material not intended for use in France.

Boston Scientific is a Global Company. Please note that model numbers, indications, contraindications, warnings and specifications may differ depending on geographic region. Not all information displayed in this brochure may be licensed in accordance with Canadian law. Please contact your Boston Scientific representative for local labeling, product specifications and licensed model numbers.

© 2023 Boston Scientific Corporation or its affiliates. All rights reserved.

EP-1506305-AA